NL194638C - Hydrosol die vaste deeltjes van een farmaceutisch actieve stof bevat en farmaceutisch preparaat dat deze hydrosol bevat. - Google Patents

Hydrosol die vaste deeltjes van een farmaceutisch actieve stof bevat en farmaceutisch preparaat dat deze hydrosol bevat. Download PDF

Info

Publication number: NL194638C
Authority: NL; Netherlands
Prior art keywords: hydrosol; cyclosporin; active substance; particles; cyclosporine
Prior art date: 1986-12-19

Application number

NL8702998A

Other languages

English (en)

Dutch (nl)

Other versions

NL194638B (nl

NL8702998A (nl

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-12-19

Filing date

1987-12-11

Publication date

2002-10-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6316557&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL194638(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1987-12-11 Application filed by Novartis Ag filed Critical Novartis Ag

1988-07-18 Publication of NL8702998A publication Critical patent/NL8702998A/nl

2002-06-03 Publication of NL194638B publication Critical patent/NL194638B/xx

2002-10-04 Application granted granted Critical

2002-10-04 Publication of NL194638C publication Critical patent/NL194638C/nl

Links

239000002245 particle Substances 0.000 title claims description 40
239000013543 active substance Substances 0.000 title claims description 18
239000007787 solid Substances 0.000 title claims description 14
239000000825 pharmaceutical preparation Substances 0.000 title claims description 5
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 38
108010036949 Cyclosporine Proteins 0.000 claims description 38
229930105110 Cyclosporin A Natural products 0.000 claims description 37
229960001265 ciclosporin Drugs 0.000 claims description 33
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
239000003381 stabilizer Substances 0.000 claims description 15
239000000725 suspension Substances 0.000 claims description 11
238000002360 preparation method Methods 0.000 claims description 10
108010010803 Gelatin Proteins 0.000 claims description 9
239000008273 gelatin Substances 0.000 claims description 9
229920000159 gelatin Polymers 0.000 claims description 9
235000019322 gelatine Nutrition 0.000 claims description 9
235000011852 gelatine desserts Nutrition 0.000 claims description 9
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
229930195725 Mannitol Natural products 0.000 claims description 6
239000000594 mannitol Substances 0.000 claims description 6
235000010355 mannitol Nutrition 0.000 claims description 6
239000002904 solvent Substances 0.000 claims description 6
239000012153 distilled water Substances 0.000 claims description 5
208000023275 Autoimmune disease Diseases 0.000 claims description 4
230000001363 autoimmune Effects 0.000 claims description 4
239000002253 acid Substances 0.000 claims description 3
238000001990 intravenous administration Methods 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
229930182912 cyclosporin Natural products 0.000 claims description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
229940125721 immunosuppressive agent Drugs 0.000 claims description 2
239000003018 immunosuppressive agent Substances 0.000 claims description 2
238000001802 infusion Methods 0.000 claims 5
230000036470 plasma concentration Effects 0.000 claims 5
206010061218 Inflammation Diseases 0.000 claims 1
208000030852 Parasitic disease Diseases 0.000 claims 1
239000004359 castor oil Substances 0.000 claims 1
235000019438 castor oil Nutrition 0.000 claims 1
201000010099 disease Diseases 0.000 claims 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 1
230000004054 inflammatory process Effects 0.000 claims 1
239000012528 membrane Substances 0.000 claims 1
239000000243 solution Substances 0.000 description 9
238000004108 freeze drying Methods 0.000 description 6
238000000034 method Methods 0.000 description 6
150000001875 compounds Chemical class 0.000 description 4
239000008131 herbal destillate Substances 0.000 description 4
230000002209 hydrophobic effect Effects 0.000 description 4
239000007788 liquid Substances 0.000 description 4
239000003960 organic solvent Substances 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
239000001856 Ethyl cellulose Substances 0.000 description 3
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
206010003246 arthritis Diseases 0.000 description 3
238000001246 colloidal dispersion Methods 0.000 description 3
229920001249 ethyl cellulose Polymers 0.000 description 3
235000019325 ethyl cellulose Nutrition 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
238000005259 measurement Methods 0.000 description 3
150000002894 organic compounds Chemical class 0.000 description 3
239000000126 substance Substances 0.000 description 3
229920002307 Dextran Polymers 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
229940102223 injectable solution Drugs 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
239000003058 plasma substitute Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 1
229920013663 Acetose Polymers 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
206010007134 Candida infections Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
208000003807 Graves Disease Diseases 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
208000029523 Interstitial Lung disease Diseases 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
208000007027 Oral Candidiasis Diseases 0.000 description 1
238000001016 Ostwald ripening Methods 0.000 description 1
206010065159 Polychondritis Diseases 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
241000287411 Turdidae Species 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 description 1
SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000002141 anti-parasite Effects 0.000 description 1
230000000842 anti-protozoal effect Effects 0.000 description 1
239000003096 antiparasitic agent Substances 0.000 description 1
239000003904 antiprotozoal agent Substances 0.000 description 1
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
201000003984 candidiasis Diseases 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
239000013078 crystal Substances 0.000 description 1
QERUYFVNIOLCHV-UHFFFAOYSA-N darodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC2=NON=C12 QERUYFVNIOLCHV-UHFFFAOYSA-N 0.000 description 1
229950009702 darodipine Drugs 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
208000007475 hemolytic anemia Diseases 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
208000016036 idiopathic nephrotic syndrome Diseases 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
229960004427 isradipine Drugs 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000004634 pharmacological analysis method Methods 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
201000003068 rheumatic fever Diseases 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
201000004409 schistosomiasis Diseases 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Physics & Mathematics (AREA)
Optics & Photonics (AREA)
Nanotechnology (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
Transplantation (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Dispersion Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NL8702998A 1986-12-19 1987-12-11 Hydrosol die vaste deeltjes van een farmaceutisch actieve stof bevat en farmaceutisch preparaat dat deze hydrosol bevat. NL194638C (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE3643392		1986-12-19
DE3643392		1986-12-19

Publications (3)

Publication Number	Publication Date
NL8702998A NL8702998A (nl)	1988-07-18
NL194638B NL194638B (nl)	2002-06-03
NL194638C true NL194638C (nl)	2002-10-04

Family

ID=6316557

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL8702998A NL194638C (nl)	1986-12-19	1987-12-11	Hydrosol die vaste deeltjes van een farmaceutisch actieve stof bevat en farmaceutisch preparaat dat deze hydrosol bevat.

Country Status (25)

Country	Link
US (1)	US5389382A (it)
JP (1)	JP2617958B2 (it)
KR (1)	KR960005136B1 (it)
AT (1)	AT397914B (it)
BE (1)	BE1000848A3 (it)
CA (1)	CA1308656C (it)
CH (1)	CH679451A5 (it)
DD (1)	DD281344A5 (it)
DE (1)	DE3742473C2 (it)
DK (2)	DK173319B1 (it)
ES (1)	ES2028492A6 (it)
FR (1)	FR2608427B1 (it)
GB (1)	GB2200048B (it)
GR (1)	GR871938B (it)
HU (1)	HU205861B (it)
IE (1)	IE61179B1 (it)
IL (1)	IL84855A (it)
IT (1)	IT1230118B (it)
LU (1)	LU87079A1 (it)
MY (1)	MY102037A (it)
NL (1)	NL194638C (it)
NZ (1)	NZ222964A (it)
PT (1)	PT86399B (it)
SE (1)	SE503020C2 (it)
ZA (1)	ZA879533B (it)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4826689A (en) *	1984-05-21	1989-05-02	University Of Rochester	Method for making uniformly sized particles from water-insoluble organic compounds
KR0148748B1 (ko) *	1988-09-16	1998-08-17	장 크라메르, 한스 루돌프 하우스	사이클로스포린을 함유하는 약학조성물
US5399363A (en) *	1991-01-25	1995-03-21	Eastman Kodak Company	Surface modified anticancer nanoparticles
US5145684A (en) *	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
DE4140172C2 (de) *	1991-12-05	1995-12-21	Alfatec Pharma Gmbh	Retardform für ein Ibuprofen enthaltendes Arzneimittel
DE4140194C2 (de) *	1991-12-05	1998-02-19	Alfatec Pharma Gmbh	Ein Dihydropyridinderivat in Nanosolform enthaltendes Arzneimittel und seine Herstellung
DE4140184C2 (de) *	1991-12-05	1995-12-21	Alfatec Pharma Gmbh	Akutform für ein Flurbiprofen enthaltendes Arzneimittel
CA2125282C (en) *	1991-12-05	1999-08-31	Jens-Christian Wunderlich	Pharmaceutically applicable nanosol and process for preparing the same
DE4140195C2 (de) *	1991-12-05	1994-10-27	Alfatec Pharma Gmbh	Pharmazeutisch applizierbares Nanosol und Verfahren zu seiner Herstellung
DE4140185C2 (de) *	1991-12-05	1996-02-01	Alfatec Pharma Gmbh	Ein 2-Arylpropionsäurederivat in Nanosolform enthaltendes Arzneimittel und seine Herstellung
DE4140183C2 (de) *	1991-12-05	1995-12-21	Alfatec Pharma Gmbh	Retardform für ein Flurbiprofen enthaltendes Arzneimittel
DE4140191C2 (de) *	1991-12-05	1998-02-19	Alfatec Pharma Gmbh	Retardform für ein Indometacin oder Acemetacin enthaltendes Arzneimittel und seine Herstellung
DE4140179C2 (de) *	1991-12-05	1995-12-21	Alfatec Pharma Gmbh	Akutform für ein Ibuprofen enthaltendes Arzneimittel
CZ278863B6 (en) *	1992-09-07	1994-07-13	Galena	Medicinal preparations with n-methylated cyclic undecapeptides
KR0146671B1 (ko) *	1994-02-25	1998-08-17	김충환	사이클로스포린-함유 분말 조성물
DE4440337A1 (de) *	1994-11-11	1996-05-15	Dds Drug Delivery Services Ges	Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5834017A (en) *	1995-08-25	1998-11-10	Sangstat Medical Corporation	Oral cyclopsporin formulations
US5827822A (en) *	1996-03-25	1998-10-27	Sangstat Medical Corporation	Cyclosporin a formulations as nanoparticles
US5766629A (en) *	1995-08-25	1998-06-16	Sangstat Medical Corporation	Oral cyclosporin formulations
US5962019A (en) *	1995-08-25	1999-10-05	Sangstat Medical Corporation	Oral cyclosporin formulations
US5858401A (en) *	1996-01-22	1999-01-12	Sidmak Laboratories, Inc.	Pharmaceutical composition for cyclosporines
EP1369111A1 (en) *	1996-10-03	2003-12-10	Hermes Biosciences, Inc.	Hydrophilic microparticles and methods to prepare same
US6249717B1 (en) *	1996-11-08	2001-06-19	Sangstat Medical Corporation	Liquid medication dispenser apparatus
US6008191A (en) *	1997-09-08	1999-12-28	Panacea Biotec Limited	Pharmaceutical compositions containing cyclosporin
US6187747B1 (en)	1997-09-08	2001-02-13	Panacea Biotech Limited	Pharmaceutical composition comprising cyclosporin
US6346511B1 (en)	1997-09-08	2002-02-12	Panacea Biotec Limited	Pharmaceutical composition comprising cyclosporin
AU750245B2 (en)	1997-10-08	2002-07-11	Aurinia Phamaceuticals Inc.	Deuterated cyclosporine analogs and their use as immunomodulating agents
US20030220234A1 (en) *	1998-11-02	2003-11-27	Selvaraj Naicker	Deuterated cyclosporine analogs and their use as immunodulating agents
DE19856432A1 (de) *	1998-12-08	2000-06-15	Basf Ag	Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
US6447806B1 (en)	1999-02-25	2002-09-10	Novartis Ag	Pharmaceutical compositions comprised of stabilized peptide particles
US6248363B1 (en) *	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20040121014A1 (en) *	1999-03-22	2004-06-24	Control Delivery Systems, Inc.	Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6217895B1 (en)	1999-03-22	2001-04-17	Control Delivery Systems	Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US20030236236A1 (en) *	1999-06-30	2003-12-25	Feng-Jing Chen	Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6656504B1 (en) *	1999-09-09	2003-12-02	Elan Pharma International Ltd.	Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
US6375972B1 (en)	2000-04-26	2002-04-23	Control Delivery Systems, Inc.	Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
DE10040707A1 (de) *	2000-08-17	2002-03-14	Braun Melsungen Ag	Kolloidale Pharmakomodulation injizierter Arzneimittel
EP2116228A1 (en) *	2001-10-19	2009-11-11	Isotechnika Inc.	Novel cyclosporin analog microemulsion preconcentrates
WO2003033526A2 (en)	2001-10-19	2003-04-24	Isotechnika Inc.	Synthesis of cyclosporin analogs
DE10205362A1 (de) *	2002-02-08	2003-08-21	Abbott Gmbh & Co Kg	Verfahren zur Herstellung wasserdispergierbarer Trockenpulver von in Wasser schwer löslichen Verbindungen
US8871241B2 (en)	2002-05-07	2014-10-28	Psivida Us, Inc.	Injectable sustained release delivery devices
DE10234784A1 (de) *	2002-07-30	2004-02-19	Günenthal GmbH	Intravenös applizierbare, pharmazeutische Darreichungsform
US7838034B2 (en)	2002-07-30	2010-11-23	Grunenthal Gmbh	Intravenous pharmaceutical form of administration
EP1592406A2 (en) *	2003-02-13	2005-11-09	Phares Pharmaceutical Research N.V.	Lipophilic compositions
US20060003002A1 (en) *	2003-11-03	2006-01-05	Lipocine, Inc.	Pharmaceutical compositions with synchronized solubilizer release
US7754243B2 (en) *	2004-08-03	2010-07-13	Clemson University Research Foundation	Aqueous suspension of nanoscale drug particles from supercritical fluid processing
DE102005011786A1 (de) *	2005-03-11	2006-09-14	Pharmasol Gmbh	Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen
JP5080445B2 (ja) *	2005-04-13	2012-11-21	アボットゲーエムベーハーウントコー．カーゲー	超微粒子懸濁液及び超微粒子を穏やかに製造する方法並びにその使用
DE102005053862A1 (de) *	2005-11-04	2007-05-10	Pharmasol Gmbh	Verfahren und Vorrichtung zur Herstellung hochfeiner Partikel sowie zur Beschichtung solcher Partikel
US9561178B2 (en) *	2006-07-25	2017-02-07	Allergan, Inc.	Cyclosporin compositions
CA2669392C (en)	2006-11-17	2016-05-10	Abbott Gmbh & Co. Kg	Nanocrystals for use in topical cosmetic formulations and method of production thereof
DE102007001473A1 (de)	2007-01-08	2008-07-10	Andreas Lemke	Verfahren zur Herstellung und Anwendung von Mikro- und/oder Nanosuspensionen durch aufbauende Mikronisierung in Gegenwart von Trockeneis und hohem Druck
CA2683712A1 (en) *	2007-04-20	2009-01-15	Sun Pharmaceutical Industries Limited	Pharmaceutical compositions
JP5149585B2 (ja) *	2007-10-02	2013-02-20	浜松ホトニクス株式会社	微粒子分散液製造方法
JP5161528B2 (ja) *	2007-10-02	2013-03-13	浜松ホトニクス株式会社	パクリタキセル微粒子、パクリタキセル微粒子分散液、および、これらの製造方法
US20090087460A1 (en) *	2007-10-02	2009-04-02	Hamamatsu Photonics K.K.	Solid composition, microparticles, microparticle dispersion liquid, and manufacturing methods for these
EP2257220B1 (en) *	2008-03-13	2017-06-14	Liebel-Flarsheim Company LLC	Multi-function, foot-activated controller for imaging system
HU230862B1 (hu)	2008-04-28	2018-10-29	DARHOLDING Vagyonkezelő Kft	Berendezés és eljárás nanorészecskék folyamatos üzemű előállítására
DE102008037025C5 (de)	2008-08-08	2016-07-07	Jesalis Pharma Gmbh	Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
US11304960B2 (en)	2009-01-08	2022-04-19	Chandrashekar Giliyar	Steroidal compositions
WO2011079232A1 (en) *	2009-12-23	2011-06-30	Psivida Us, Inc.	Sustained release delivery devices
US9358241B2 (en)	2010-11-30	2016-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20180153904A1 (en)	2010-11-30	2018-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9034858B2 (en)	2010-11-30	2015-05-19	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20120148675A1 (en)	2010-12-10	2012-06-14	Basawaraj Chickmath	Testosterone undecanoate compositions
EP2583672A1 (en)	2011-10-17	2013-04-24	PharmaSol GmbH	Nanocrystals and amorphous nanoparticles and method for production of the same by a low energy process
WO2015071841A1 (en)	2013-11-12	2015-05-21	Druggability Technologies Holdings Limited	Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US9498485B2 (en)	2014-08-28	2016-11-22	Lipocine Inc.	Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170246187A1 (en)	2014-08-28	2017-08-31	Lipocine Inc.	(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20160361322A1 (en)	2015-06-15	2016-12-15	Lipocine Inc.	Composition and method for oral delivery of androgen prodrugs
US20180147215A1 (en)	2016-11-28	2018-05-31	Lipocine Inc.	Oral testosterone undecanoate therapy
US12150945B2 (en)	2018-07-20	2024-11-26	Lipocine Inc.	Liver disease
EP3616688A1 (en) *	2018-08-27	2020-03-04	Centre National de la Recherche Scientifique - CNRS	Preparation of nanosuspension comprising nanocrystals of active pharmaceutical ingredients with little or no stabilizing agents

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US107288A (en) *		1870-09-13		Improvement in thread-spools
DE738604C (de) *	1935-07-09	1943-08-23	Rudolf Degkwitz Dr	Verfahren zur Herstellung von Hydrosolen mit waehlbarer Gestalt und waehlbarer Groesse der kolloiden Teilchen
JPS5831210B2 (ja) *	1973-04-09	1983-07-05	武田薬品工業株式会社	アンテイナスイセイケンダクエキノセイゾウホウ
DE2362785A1 (de) *	1973-12-18	1975-06-26	Atmos Fritzsching & Co Gmbh	Verfahren zum haltbarmachen von kristallsuspensionen
FR2257266B1 (it) *	1974-01-10	1977-07-01	Pasteur Institut
US4107288A (en) *	1974-09-18	1978-08-15	Pharmaceutical Society Of Victoria	Injectable compositions, nanoparticles useful therein, and process of manufacturing same
CA1098444A (en) *	1975-05-26	1981-03-31	Leo Geller	Peptide preparations with prolonged action
US4117118A (en) *	1976-04-09	1978-09-26	Sandoz Ltd.	Organic compounds
IT1142172B (it) *	1978-10-19	1986-10-08	Sandoz Ag	Nuovo impiego in terapeutica della ciclosporina-a e della diidrociclosporina-c
DE3013839A1 (de) *	1979-04-13	1980-10-30	Freunt Ind Co Ltd	Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US4361580A (en) *	1980-06-20	1982-11-30	The Upjohn Manufacturing Company	Aluminum ibuprofen pharmaceutical suspensions
IT1209276B (it) *	1980-11-05	1989-07-16	Magis Farmaceutici	Composizione farmaceutica per la somministrazione orale del metilestere dell'acido 13a-etil-2,3,5,6,12,13,13a,13b-ottaidro-12-idrossi1h-indolo-[3,2,1-de] pirido [3,2,1-ij] [1,5] naftiridina -12-carbossilico
PH20649A (en) *	1981-09-22	1987-03-16	Gist Brocades Nv	Bismuth containing composition and method for the preparation thereof
GB8322364D0 (en) *	1983-08-19	1983-09-21	May & Baker Ltd	Compositions of matter
CA1239349A (en) *	1983-10-10	1988-07-19	Eberhard F. Gottwald	Pharmaceutical composition containing cimetidine
EP0138216B1 (en) *	1983-10-14	1993-01-07	Sumitomo Pharmaceuticals Company, Limited	Sustained-release ifn preparation for parenteral administration
JPS60139688A (ja) *	1983-12-28	1985-07-24	Tokyo Tanabe Co Ltd	無定形ジヒドロピリジン粉末製剤
DE3347579A1 (de) *	1983-12-30	1985-07-11	Hoechst Ag, 6230 Frankfurt	Zubereitungen schwer wasserloeslicher anthelminthika und verfahren zu ihrer herstellung
CA1282405C (en) *	1984-05-21	1991-04-02	Michael R. Violante	Method for making uniformly sized particles from water-insoluble organic compounds
IE58110B1 (en) *	1984-10-30	1993-07-14	Elan Corp Plc	Controlled release powder and process for its preparation
DE3515335C2 (de) *	1985-04-27	1995-01-26	Bayer Ag	Arzneizubereitung enthaltend Dihydropyridine und Verfahren zu ihrer Herstellung

1987
- 1987-12-11 NL NL8702998A patent/NL194638C/nl not_active IP Right Cessation
- 1987-12-11 HU HU875601A patent/HU205861B/hu unknown
- 1987-12-15 DE DE3742473A patent/DE3742473C2/de not_active Expired - Lifetime
- 1987-12-15 CH CH4885/87A patent/CH679451A5/de not_active IP Right Cessation
- 1987-12-17 PT PT86399A patent/PT86399B/pt not_active IP Right Cessation
- 1987-12-17 CA CA000554625A patent/CA1308656C/en not_active Expired - Lifetime
- 1987-12-17 AT AT0333087A patent/AT397914B/de not_active IP Right Cessation
- 1987-12-17 GB GB8729404A patent/GB2200048B/en not_active Expired - Lifetime
- 1987-12-17 DD DD87310651A patent/DD281344A5/de not_active IP Right Cessation
- 1987-12-17 GR GR871938A patent/GR871938B/el unknown
- 1987-12-17 SE SE8705043A patent/SE503020C2/sv not_active IP Right Cessation
- 1987-12-17 DK DK198706641A patent/DK173319B1/da not_active IP Right Cessation
- 1987-12-17 LU LU87079A patent/LU87079A1/fr unknown
- 1987-12-17 BE BE8701461A patent/BE1000848A3/fr not_active IP Right Cessation
- 1987-12-17 FR FR878717792A patent/FR2608427B1/fr not_active Expired - Lifetime
- 1987-12-17 IL IL84855A patent/IL84855A/xx not_active IP Right Cessation
- 1987-12-17 IE IE342587A patent/IE61179B1/en not_active IP Right Cessation
- 1987-12-17 NZ NZ222964A patent/NZ222964A/xx unknown
- 1987-12-18 KR KR1019870014499A patent/KR960005136B1/ko not_active Expired - Lifetime
- 1987-12-18 IT IT8748729A patent/IT1230118B/it active
- 1987-12-18 ZA ZA879533A patent/ZA879533B/xx unknown
- 1987-12-18 MY MYPI87003217A patent/MY102037A/en unknown
- 1987-12-18 JP JP62322622A patent/JP2617958B2/ja not_active Expired - Lifetime
- 1987-12-18 ES ES8703635A patent/ES2028492A6/es not_active Expired - Lifetime
1991
- 1991-01-16 US US07/642,106 patent/US5389382A/en not_active Expired - Lifetime
2000
- 2000-02-21 DK DK200000266A patent/DK173345B1/da not_active IP Right Cessation

Also Published As

Publication number	Publication date
HUT52941A (en)	1990-09-28
DD281344A5 (de)	1990-08-08
NL194638B (nl)	2002-06-03
KR880007061A (ko)	1988-08-26
FR2608427B1 (fr)	1991-02-08
SE8705043L (sv)	1988-06-20
FR2608427A1 (fr)	1988-06-24
GR871938B (en)	1988-04-05
AU606908B2 (en)	1991-02-21
BE1000848A3 (fr)	1989-04-18
IT1230118B (it)	1991-10-07
DE3742473A1 (de)	1988-07-28
PT86399B (pt)	1994-10-31
GB2200048A (en)	1988-07-27
JP2617958B2 (ja)	1997-06-11
IL84855A (en)	1992-03-29
PT86399A (pt)	1989-01-17
DE3742473C2 (de)	1998-11-19
IL84855A0 (en)	1988-06-30
IT8748729A0 (it)	1987-12-18
DK173345B1 (da)	2000-08-07
MY102037A (en)	1992-02-29
DK200000266A (da)	2000-02-21
IE873425L (en)	1988-06-19
DK664187A (da)	1988-06-20
SE8705043D0 (sv)	1987-12-17
JPS63165312A (ja)	1988-07-08
HU205861B (en)	1992-07-28
ZA879533B (en)	1989-08-30
KR960005136B1 (ko)	1996-04-22
AT397914B (de)	1994-08-25
CH679451A5 (it)	1992-02-28
SE503020C2 (sv)	1996-03-11
ES2028492A6 (es)	1992-07-01
NL8702998A (nl)	1988-07-18
IE61179B1 (en)	1994-10-05
NZ222964A (en)	1991-01-29
US5389382A (en)	1995-02-14
LU87079A1 (fr)	1988-07-14
DK664187D0 (da)	1987-12-17
ATA333087A (de)	1993-12-15
AU8282887A (en)	1988-06-23
GB2200048B (en)	1991-02-06
DK173319B1 (da)	2000-07-24
GB8729404D0 (en)	1988-02-03
CA1308656C (en)	1992-10-13

Legal Events

Date	Code	Title	Description
1994-08-01	BA	A request for search or an international-type search has been filed
1994-09-01	BB	A search report has been drawn up
1995-01-02	BC	A request for examination has been filed
1997-11-03	CNR	Transfer of rights (patent application after its laying open for public inspection)	Free format text: NOVARTIS AG
2008-02-01	V4	Discontinued because of reaching the maximum lifetime of a patent	Effective date: 20071211

Publication	Publication Date	Title
US5389382A (en)	1995-02-14	Hydrosols of pharmacologically active agents and their pharmaceutical compositions comprising them
CA2108018C (en)	2003-04-15	Colloidal particles of water insoluble biologically active substances
US6447806B1 (en)	2002-09-10	Pharmaceutical compositions comprised of stabilized peptide particles
EP0161445B1 (en)	1988-09-21	Water soluble drug complex and method for production of same
JP4073641B2 (ja)	2008-04-09	新規シクロスポリン製剤
CA1336890C (en)	1995-09-05	Amphotericin b/cholesterol sulfate composition and method
US12303606B2 (en)	2025-05-20	Cariprazine release formulations
JP2000501989A (ja)	2000-02-22	無菌条件下にろ過可能な安定化されたナノ粒子
RU2178293C2 (ru)	2002-01-20	Фармацевтическая композиция, содержащая циклоспорин, способ получения мягких желатиновых капсул
JPH04234820A (ja)	1992-08-24	長期作用持続性リポソームペプチド薬学的生成物およびそれらの調製方法
JPH0558410B2 (it)	1993-08-26
CN113244190A (zh)	2021-08-13	一种胶束模板法制备的虾青素长效纳米制剂及其制法
Dhawan et al.	1991	In vitro evaluation of albumin microspheres containing actinomycin D
HK1099916B (en)	2018-04-20	Use of glycerol dipalmitostearate for improving the bioavailability of protein active ingredients in subcutaneous or intramuscular injectable formulations